LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1537-1539

  Hurtado, C ^a   Erquiaga, I ^a   Aranaz, P ^a   Migueliz I ^a   Garcia Delgado M ^a   Novo, F J ^a   Vizmanos, J L ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; PHENYLALANINE; PLECKSTRIN HOMOLOGY DOMAIN PROTEIN; PROTEIN SH2; UNCLASSIFIED DRUG; VALINE;

ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; EOSINOPHILIC LEUKEMIA; EXON; GENE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; JAK2 GENE; LNK GENE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA;

BLOOD PROTEINS; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHOSPHOPROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTEINS; SRC HOMOLOGY DOMAINS;

EID: 80053969987     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.009     Document Type: Article

References (14)

1. Rudd C.E. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci STKE 2001, 2001(June (85)):pe1.
2. Gery S., Gueller S., Nowak V., Sohn J., Hofmann W.K., Koeffler H.P. Expression of the adaptor protein Lnk in leukemia cells. Exp Hematol 2009, 37(5):585-592.
3. Velazquez L., Cheng A.M., Fleming H.E., Furlonger C., Vesely S., Bernstein A., et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002, 195(12):1599-1611.
4. Gudbjartsson D.F., Bjornsdottir U.S., Halapi E., Helgadottir A., Sulem P., Jonsdottir G.M., et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009, 41(3):342-347.
5. Levy D., Ehret G.B., Rice K., Verwoert G.C., Launer L.J., Dehghan A., et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41(6):677-687.
6. Newton-Cheh C., Johnson T., Gateva V., Tobin M.D., Bochud M., Coin L., et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41(6):666-676.
7. Oh S.T., Simonds E.F., Jones C., Hale M.B., Goltsev Y., Gibbs K.D., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116(6):988-992.
8. Oh S.T., Zahn J.M., Jones C.D., Zhang B., Loh M.L., Kantarjian H.M., et al. Identification of novel LNK mutations in patients with chronic myeloproliferative neoplasms and related disorders. Blood [ASH Annual Meeting Abstracts] 2010, 116(21). Abstract # 315.
9. Lasho T.L., Pardanani A., Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010, 363:1189-1190.
10. Aranaz P., Ormazábal C., Hurtado C., Erquiaga I., Calasanz M.J., García-Delgado M., et al. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. Cancer Genet Cytogenet 2010, 199(1):1-8.
11. Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., et al. Nat Methods 2010, 7(4):248-249.
12. Lasho T.L., Tefferi A., Vannucchi A.M., Finke C., Guglielmelli P., Pieri L., et al. LNK mutation studies in chronic- and blast-phase myeloproliferative neoplasms and JAK2 mutation-negative erythrocytosis. Blood [ASH Annual Meeting Abstracts] 2010, 116(21). Abstract # 4105.
13. Lasho T.L., Tefferi A., Finke C., Pardanani A. Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations. Leukemia 2011, March 18 [Epub ahead of print].
14. Pardanani A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010, 24:1713-1718.